InMed Pharmaceuticals (INM) Operating Income (2021 - 2025)

InMed Pharmaceuticals has reported Operating Income for 5 years, with the latest figure at -$2.1 million in Q4 2025.

• On a quarterly basis, Operating Income rose 6.72% year-over-year to -$2.1 million in Q4 2025; TTM through Dec 2025 was -$8.3 million, a 5.49% decrease from a year earlier, with the FY2025 full-year figure at -$7.9 million, up 3.05% from the prior year.
• Operating Income was -$2.1 million for Q4 2025 at InMed Pharmaceuticals, down from -$1.8 million in the prior quarter.
• The five-year high for Operating Income was -$485150.0 in Q2 2023, with the low at -$6.5 million in Q2 2022.
• Average Operating Income over 5 years is -$2.5 million, with a median of -$2.2 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Operating Income jumped 92.56% in 2023, then sank 319.3% in 2024.
• Over 5 years, Operating Income stood at -$4.3 million in 2021, then jumped by 48.66% to -$2.2 million in 2022, then gained by 25.7% to -$1.6 million in 2023, then slumped by 37.03% to -$2.3 million in 2024, then rose by 6.72% to -$2.1 million in 2025.
• The last three Operating Income figures came in at -$2.1 million (Q4 2025), -$1.8 million (Q3 2025), and -$2.5 million (Q2 2025), per Business Quant data.